MedTrace Logo

Safety, Efficacy and Tolerability of Vilazodone in Generalized Anxiety Disorder

NCT01629966 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 680

Last updated 2019-12-18

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to evaluate the efficacy, safety and tolerability of vilazodone relative to placebo in the treatment of generalized anxiety disorder (GAD)

Conditions

  • Generalized Anxiety Disorder

Interventions

DRUG

Placebo

Matching 10 mg and 20 mg placebo tablets, once per day, oral administration,

DRUG

Vilazodone

Vilazodone, 20mg, oral administration once per day.

DRUG

Vilazodone

Vilazodone, 40mg, oral administration once per day.

Sponsors & Collaborators

  • Forest Laboratories

    lead INDUSTRY

Principal Investigators

  • Giovanna Forero, MA · Forest Laboratories

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2012-06-30
Primary Completion
2014-02-28
Completion
2014-03-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01629966 on ClinicalTrials.gov